ArticleCytotechnology2025
DNA methyltransferase DNMT3A inhibits TP53AIP1 expression and promotes cervical cancer development and metastasis.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DNMT Enzymes and Their Impact on Cervical Cancer: A State-of-the-Art Review.International journal of molecular sciences · 2025Review
- Genetic Investigation and Transcriptome Profiling in a Nuclear Family With Peutz-Jeghers Syndrome.Human mutation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) patients have a poor prognosis and a low 1-year survival rate due to recurrence or pelvic metastasis. The GSE9750 dataset was analyzed to identify hub genes in CC. CCK-8, colony formation assay, EdU, TUNEL, Transwell assays, and western blot analysis for apoptosis-associated markers were conducted to examine CC cell malignant phenotype after different lentiviral vector treatments. Dual-luciferase assay, ChIP, and MSP were used for regulatory assays. P53-regulated apoptosis-inducing protein 1 (TP53AIP1) was lowly expressed in CC tissues and cell lines, and TP53AIP1 overexpression repressed proliferation, migration, and invasion, and induced apoptosis of CC cells by activating the p53 signaling. DNMT3A bound to the TP53AIP1 promoter and transcriptionally repressed TP53AIP1 expression. DNA-methyltransferase 3A (DNMT3A) silencing inhibited CC development and lung metastasis in vivo, but further TP53AIP1 knockdown reversed this phenomenon by disrupting p53-mediated apoptosis. In summary, DNMT3A transcriptionally repressed TP53AIP1 expression to promote CC progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.